CYTK: Cytokinetics Inc.
Performance
CYTK -8.34%
Watchlist
Select an item
Summary
CYTK at a glance
CYTK returned -8.34% over the past year and +6.04% a year over five years. Its worst drop in that year was -38.47%, smaller than 40% of stocks on Redstone, and its Sharpe ratio of -0.07 beats 24% of stocks on Redstone. It pays no dividends.
Current Drawdown
-36.81%
Rolling Volatility
52.19%
Actions
Metrics
Risk Indicators
Alpha-12.70%
Beta1.00x
Sharpe-0.07
Sortino-0.09
Omega0.99
Calmar-0.22
Martin-0.21
Profile
About CYTK
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $7.7B
- Listed
- Apr 2004
- Employees
- 673
- Headquarters
- South San Francisco, CA
- Website
- cytokinetics.com
Comparisons